WebDec 18, 2024 · Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia and … WebDec 14, 2024 · Dr. Richter is a member of the international myeloma working group and have acted as principle investigator and sub-investigator on dozens of clinical trials in …
How Often to Receive MRD Testing During Remission - Myeloma …
Web1 day ago · During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, discussed considerations when using selinexor with various drug combinations in later-line multiple myeloma therapy. This is the second of 2 articles based on this event. WebJun 2, 2024 · Multiple Myeloma Approvals Likely in 2024 Dr. Richter expects to see FDA approvals of bispecific antibodies or agents as early as 2024. These are antibody molecules with two arms. One arm targets BCMA, the other targets CD3, a marker on the T-cells. containers that fit in pottery barn lunch box
The Pandemic
WebJoshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. WebOct 4, 2024 · Dr. Joshua Richter: Welcome to this Cancer Network, Between The Lines program. Today's featured article is Guidelines for Use and Dosing of Selinexor in … effect of vehicular accident